192944-51-7

Basic information

• Product Name: ETHYL 1H-INDAZOLE-5-CARBOXYLATE
• Synonyms: 1H-INDAZOLE-5-CARBOXYLIC ACID ETHYL ESTER;ETHYL 1H-INDAZOLE-5-CARBOXYLATE;1H-Indazole-5-carboxylicacid,ethylester(9CI);5-(Ethoxycarbonyl)-1H-indazole;Ethyl Indazole-5-carboxylate;ETHYL 1H-INDAZOLE-5-CARBOXYLAT
• CAS NO: 192944-51-7
• Molecular Formula: C₁₀H₁₀N₂O₂
• Molecular Weight: 190.2
• Product Categories: CARBOXYLICESTER;pharmacetical
• Mol File: 192944-51-7.mol

Chemical Properties

• Melting Point: 122-124℃
• Boiling Point: 353.9°Cat760mmHg
• Flash Point: 167.8°C
• Appearance: /
• Density: 1.272g/cm³
• Vapor Pressure: 3.47E-05mmHg at 25°C
• Refractive Index: 1.627
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 12.81±0.40(Predicted)
• CAS DataBase Reference: ETHYL 1H-INDAZOLE-5-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 1H-INDAZOLE-5-CARBOXYLATE(192944-51-7)
• EPA Substance Registry System: ETHYL 1H-INDAZOLE-5-CARBOXYLATE(192944-51-7)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 192944-51-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
ETHYL 1H-INDAZOLE-5-CARBOXYLATE is used as a research compound for its potential biological activities, particularly in the development of anti-inflammatory and anti-cancer drugs. Its unique chemical structure and properties make it a promising candidate for the discovery of new therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, ETHYL 1H-INDAZOLE-5-CARBOXYLATE serves as a key intermediate or building block in the synthesis of more complex organic molecules. Its reactivity and functional groups allow for various chemical transformations, contributing to the creation of novel compounds with diverse applications.
Used in Drug Development:
ETHYL 1H-INDAZOLE-5-CARBOXYLATE is utilized in drug development as a lead compound or a template for the design of new pharmaceuticals. Its anti-inflammatory and anti-cancer properties make it a valuable asset in the search for effective treatments for various diseases and conditions.
Used in Chemical Research:
In chemical research, ETHYL 1H-INDAZOLE-5-CARBOXYLATE is employed to study the properties and reactivity of indazole-based compounds. Understanding its behavior in different chemical reactions can provide insights into the development of new synthetic methods and the discovery of new chemical entities.
Used in Material Science:
Although not explicitly mentioned in the provided materials, the potential applications of ETHYL 1H-INDAZOLE-5-CARBOXYLATE in material science could be explored, given its unique chemical structure. It may be used in the development of new materials with specific properties, such as optoelectronic materials, sensors, or other advanced materials.

InChI:InChI=1/C10H10N2O2/c1-2-14-10(13)7-3-4-9-8(5-7)6-11-12-9/h3-6H,2H2,1H3,(H,11,12)

Upstream product

• 64-17-5 ethanol 
• 61700-61-6 1H-indazole-5-carboxylic acid 
• 40800-65-5 1-amino-2-methylbenzene-4-carboxylic acid ethyl ester 
• 2486-70-6 4-amino 3-methylbenzoic acid 
• 108-24-7 acetic anhydride 
• 192944-50-6 ethyl 1-acetyl-1H-indazole-5-carboxylatee 

Downstream Products

• 1005205-25-3 1H-indazole-5-carbohydrazide 

Relevant articles and documents

Identification of N-acylhydrazone derivatives as novel lactate dehydrogenase A inhibitors

Abstract Glycolysis is drastically increased in tumors and it is the main route to energy production with a minor use of oxidative phosphorylation. Among the key enzymes in the glycolytic process, LDH is emerging as one of the most interesting targets for the development of new inhibitors. In this context, in the present work, we carried out a virtual screening procedure followed by chemical modifications of the identified structures according to a "hit-to-lead" process. The effects of the new molecules were preliminary probed against purified human LDH-A. The compounds active at low micromolar level were additionally characterized for their activity on some cellular metabolic processes by using Raji human cell line. Within the series, 1 was considered the best candidate, and a more detailed characterization of its biological properties was performed. In Raji cells exposed to compound 1 we evidenced the occurrence of effects usually observed in cancer cells after LDH-A inhibition: reduced lactate production and NAD/NADH ratio, apoptosis. The flow cytometry analysis of treated cells also showed cell cycle changes compatible with effects exerted at the glycolytic level. Finally, in agreement with the data obtained with other inhibitors or by silencing LDH-A expression, compound 1 was found to increase Raji cells response to some commonly used chemotherapeutic agents. Taken together, all these finding are in support of the LDH-A inhibiting activity of compound 1.

HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR

A novel heterocyclic compound or a salt thereof useful for selectively inhibiting the degradation of p27Kip1 is provided. The compound or the salt thereof is represented by the following formula (1): wherein A represents an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic group, the group A may have a substituent; the ring B represents a 5- to 8-membered monocyclic heterocyclic ring or a condensed ring containing the monocyclic heterocyclic ring, the ring B may have a substituent; the ring C represents an aromatic ring, the ring C may have a substituent; L represents a linker comprising a main chain having 3 to 5 atoms selected from the group consisting of a carbon atom, a nitrogen atom, an oxygen atom and a sulfur atom, wherein at least one atom in the main chain is a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, the linker L may have a substituent; and n is 0 or 1.

Integrin antagonists

This invention relates to novel heterocycles which are useful as antagonists of the αvβ3 integrin, the α2bβ3 integrin, and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

Disubstituted indazoles as potent antagonists of the integrin α(v)β3

A new series of indazole-containing α(v)β3 integrin antagonists is described. Starting with lead compound 18a, variations in a number of structural features were explored with respect to inhibition of the binding of β3-transfected 29

Integrin receptor antagonists

This invention relates to novel heterocycles including 3-?1-?3-(imidazolin-2-ylamino)propyl!indazol-5-ylcarbonylamino!-2-(benzyloxycarbonylamino)propionic acid, which are useful as antagonists of the αv β3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.